Home / Compare / BPC-157 vs TB-500
BPC-157 vs TB-500
BPC-157 · TB-500
The short answer
Neither has been shown to work in humans. That is not a dodge, it is the answer.
For BPC-157, a 2025 systematic review of orthopaedic applications screened 544 articles and found one clinical study. For TB-500 as sold, there is no human trial evidence at all. Asking which is better is asking which of two untested compounds is more untested.
They are usually sold together, as the Wolverine stack, which does not improve matters.
Everything below goes into the detail, with sources on each record.
01Side by side
| BPC-157 | TB-500 | |
|---|---|---|
| UK status | Unlicensed medicine | Unlicensed medicine |
| Availability | Research use only | Research use only |
| Evidence base | Animal studies, almost no human data | Animal studies, no human trials |
| Controlled drug | No, but WADA prohibited | No, but WADA prohibited |
| Drug class | Synthetic pentadecapeptide | Synthetic peptide fragment |
02What is the same
- Both unlicensed medicines in the UK. Supplying either for human use without MHRA authorisation is prohibited.
- Both sold as research chemicals labelled not for human consumption, a label describing the seller's legal position rather than the product.
- Both marketed for tendon, ligament, muscle and general recovery.
- Both prohibited by WADA at all times. BPC-157 under S0, TB-500 as a thymosin beta-4 derivative under growth factors.
- Neither has an established safety profile, because that comes from regulated trials and there have not been any.
- Both were recommended for US compounding by an FDA advisory committee in July 2026, against the agency's own scientists. That is not approval and changes nothing in the UK.
03What actually differs
The differences are in origin and in the shape of the evidence gap, not in whether either works.
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | 15 amino acids, from a protein in gastric juice | A short fragment of thymosin beta-4 |
| Animal evidence | Extensive, three decades, largely one research group | Exists, mostly on the full protein rather than the fragment |
| Human evidence | One clinical study in a 544-article review | None for the compound as sold |
| Proposed mechanism | New blood vessel growth into damaged tissue | Cell migration into damaged tissue |
| The marketing problem | Rodent results presented as human evidence | Research on the full protein presented as evidence for the fragment |
TB-500 is a fragment, not thymosin beta-4 itself, and marketing uses the names interchangeably. When you read a study, check which molecule it used. That single check disposes of a lot of what gets cited.
04What the evidence says
BPC-157 has the larger animal literature by a distance, produced over three decades largely by one group in Zagreb. It reports healing effects across many rodent models. Most compounds that work in rodents fail in people, so that is a reason to run trials rather than a substitute for them.
TB-500's supporting literature is mostly about thymosin beta-4, the full protein, on which some clinical work exists for specific indications such as corneal and skin wound healing. That work does not automatically transfer to the fragment.
In April 2026 the FDA opened an MHRA-unrelated door by removing both from its Category 2 safety-concern list after nominations were withdrawn, without moving them to the permitted list. In July 2026 its advisory committee recommended both for compounding, 8 to 6, over the objections of FDA reviewers who cited immunogenicity, peptide impurities and limited safety data.
05Which suits whom
The honest version of this section is that there is no "who".
If you have an injury, there are treatments with evidence: physiotherapy, load management, sometimes injections or surgery, all of which have been tested and all of which come with someone accountable if they go wrong. Those are boring compared to a peptide, and they are what the evidence supports.
If you compete in a tested sport, both compounds are prohibited at all times and strict liability means your intent is irrelevant.
06Getting either in the UK
Neither has MHRA authorisation. Both can be sold lawfully as research chemicals in the UK; supplying either for human use is prohibited.
The MHRA opened an investigation in April 2026 into UK clinics making therapeutic claims about unregulated peptides, and BPC-157 was reported as the first compound named.
07The honest bottom line
There is no winner here, and picking one is not the decision in front of you.
The decision is whether to inject an unlicensed compound of unverifiable contents on the strength of animal research and forum consensus. Both records lay out what is actually known, which for both is considerably less than the marketing implies.
08Common questions
Which is better, BPC-157 or TB-500?
Neither has been shown to work in humans, so the question has no evidence-based answer. BPC-157 has the larger animal literature; TB-500 has essentially no human data for the compound as sold.
Should I take them together?
The argument for combining them is that they act on different parts of tissue repair. The problem is that neither has been shown to work alone, and combining two unproven compounds doubles every purity, sterility and interaction unknown rather than adding two benefits.
Did the FDA just approve them?
No. An advisory committee recommended them for a list of substances US compounding pharmacies may prepare, 8 to 6, against the FDA's own reviewers. That is not approval, requires rulemaking that typically takes 8 to 12 months, and has no effect in the UK.
Are they legal in the UK?
Both are unlicensed medicines. Neither is a controlled drug, but supplying either for human use without MHRA authorisation is prohibited under the Human Medicines Regulations 2012.
Full record
BPC-157
Heavily marketed for healing and recovery. The human evidence is close to nonexistent.
Full record
TB-500
Sold alongside BPC-157 for the same claimed purposes, with the same evidence problem.
Get told when something changes
A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address. Unsubscribe whenever.